Compare ALLE & UTHR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | ALLE | UTHR |
|---|---|---|
| Founded | 2013 | 1996 |
| Country | Ireland | United States |
| Employees | N/A | N/A |
| Industry | Diversified Commercial Services | Biotechnology: Pharmaceutical Preparations |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 13.9B | 20.3B |
| IPO Year | N/A | 1999 |
| Metric | ALLE | UTHR |
|---|---|---|
| Price | $159.24 | $488.92 |
| Analyst Decision | Hold | Buy |
| Analyst Count | 9 | 12 |
| Target Price | $172.22 | ★ $495.08 |
| AVG Volume (30 Days) | ★ 787.1K | 424.3K |
| Earning Date | 10-23-2025 | 10-29-2025 |
| Dividend Yield | ★ 1.28% | N/A |
| EPS Growth | 13.70 | ★ 16.08 |
| EPS | 7.39 | ★ 26.38 |
| Revenue | ★ $3,979,700,000.00 | $3,128,400,000.00 |
| Revenue This Year | $10.07 | $13.64 |
| Revenue Next Year | $6.53 | $5.78 |
| P/E Ratio | $21.53 | ★ $18.55 |
| Revenue Growth | 6.87 | ★ 13.50 |
| 52 Week Low | $116.57 | $266.98 |
| 52 Week High | $180.68 | $492.62 |
| Indicator | ALLE | UTHR |
|---|---|---|
| Relative Strength Index (RSI) | 35.06 | 68.10 |
| Support Level | $163.27 | $470.13 |
| Resistance Level | $167.01 | $492.62 |
| Average True Range (ATR) | 3.10 | 10.72 |
| MACD | 0.01 | -0.53 |
| Stochastic Oscillator | 2.11 | 89.55 |
Allegion is a global security products company with a portfolio of leading brands such as Schlage, Von Duprin, and LCN. The Ireland-domiciled company was created via a spinoff transaction from Ingersoll-Rand in December 2013. In fiscal 2024, Allegion generated over 75% of sales in the United States. The company primarily competes with Sweden-based Assa Abloy, Switzerland-based Dormakaba, and US-based Fortune Brands Innovations.
United Therapeutics Corp specializes in drug development for pulmonary arterial hypertension (PAH), a rare and progressive disease marked by abnormally high blood pressure in the arteries of the lungs. The company's therapies for PAH largely focus on the prostacyclin pathway, and many of its treatments are based on the same molecule, treprostinil. The company markets and sells the following commercial therapies in the United States to treat PAH: Tyvaso DPI (treprostinil) Inhalation Powder, Remodulin Injection, Orenitram (treprostinil) Extended-Release Tablets, Adcirca (tadalafil) Tablets, and Unituxin. In addition, it is developing a pipeline of projects that includes new indications and delivery devices for existing products and new products to treat PAH and other conditions.